Last reviewed · How we verify
Seroquel (quetiapine)
Quetiapine blocks dopamine and serotonin receptors in the brain to reduce psychotic symptoms and stabilize mood.
Quetiapine blocks dopamine and serotonin receptors in the brain to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia, Bipolar disorder (acute mania and maintenance), Major depressive disorder (adjunctive treatment).
At a glance
| Generic name | Seroquel (quetiapine) |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor, serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Quetiapine is an atypical antipsychotic that antagonizes dopamine D2 receptors and serotonin 5-HT2A receptors, which are implicated in psychosis and mood dysregulation. It also has activity at other receptors including alpha-adrenergic and histamine receptors, contributing to its sedating properties and broader psychiatric effects.
Approved indications
- Schizophrenia
- Bipolar disorder (acute mania and maintenance)
- Major depressive disorder (adjunctive treatment)
- Generalized anxiety disorder
Common side effects
- Somnolence/sedation
- Dry mouth
- Dizziness
- Weight gain
- Headache
- Constipation
- Tachycardia
Key clinical trials
- An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine (PHASE4)
- Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure (PHASE3)
- A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia. (PHASE3)
- Sequential Multiple Assignment Randomized Trial for Bipolar Depression (PHASE4)
- Magnetic Seizure Therapy for Psychotic Disorders (NA)
- National Pregnancy Registry for Psychiatric Medications
- The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. (PHASE3)
- Comparing Antipsychotic Medications in LBD Over Time (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Seroquel (quetiapine) CI brief — competitive landscape report
- Seroquel (quetiapine) updates RSS · CI watch RSS
- AstraZeneca portfolio CI